Teva Pharmaceutical Industries Ltd. has achieved major progress in its biosimilar portfolio by securing U.S. Food and Drug Administration approval for PONLIMSI™ (denosumab‑adet) and acceptance of dual regulatory filings for its biosimilar candidate to Xolair® (omalizumab). The company, aiming to transform into a leading biopharmaceutical entity, highlighted these milestones as key drivers of its Pivot to Growth strategy and global competitiveness.
The FDA approval of PONLIMSI marks a significant regulatory achievement for Teva, allowing commercialisation of the denosumab‑based biosimilar across all indications of its reference product, Prolia®. This expanded treatment option targets patients at high risk of fractures due to osteoporosis and similar conditions. In addition, both the U.S. FDA and European Medicines Agency (EMA) have accepted Teva’s regulatory submissions for its proposed omalizumab biosimilar candidate, demonstrating broad international momentum.
In an official statement, Teva’s Head of Biosimilars R&D underscored the robust scientific and operational efforts behind these developments. By leveraging internal expertise alongside strategic partnerships, the company continues to strengthen its biosimilar portfolio with products designed to expand access to critical therapies and support long‑term growth.
The FDA approval of PONLIMSI was granted after a comprehensive evaluation of analytical and clinical data, which confirmed a similar efficacy, safety, and immunogenicity profile to its reference product, Prolia®. This approval encompasses various approved uses of Prolia®, including treatment of postmenopausal women and men with osteoporosis at high risk for fracture, as well as patients undergoing therapies linked with bone loss.
With the regulatory decision now in place, PONLIMSI can be offered to a wide range of patients, including those with glucocorticoid‑induced osteoporosis or individuals with increased fracture risk due to cancer therapy. This approval aligns with Teva’s strategy of expanding patient access to high‑quality biosimilar alternatives that have the potential to reduce treatment costs.
“The FDA approval of PONLIMSI showcases our deep clinical and regulatory capabilities and strengthens our commitment to delivering additional treatment options for patients worldwide,” said Teva’s Global Head of Biosimilars. She added that the dual acceptance of the omalizumab biosimilar filings in both the U.S. and Europe further highlights the company’s expanding global footprint.
Alongside the PONLIMSI milestone, Teva’s proposed biosimilar candidate to Xolair® has progressed through regulatory channels with the acceptance of its Biologics License Application in the U.S. and Marketing Authorization Application in the European Union. These submissions include all indications approved for Xolair®, spanning moderate‑to‑severe allergic asthma, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, and IgE‑mediated food allergies in eligible age groups.
This dual regulatory engagement reflects Teva’s ongoing commitment to diversifying its portfolio of complex biologic alternatives. Should approval be granted, the omalizumab biosimilar candidate could offer clinicians and patients a competitive treatment option across multiple allergic and immunological conditions.
Industry analysts note that Teva’s biosimilar achievements come amid an increasingly competitive landscape, where reducing the cost of biologic therapies remains a priority for healthcare systems worldwide. By bringing high‑quality biosimilar treatments to market, companies like Teva help foster competition, which can ultimately lead to better access and more sustainable pricing.
The company’s broader strategy emphasizes strengthening its product offerings in key therapeutic areas, including immunology, oncology, and respiratory medicine, by advancing both early‑stage and late‑stage biosimilar programs. With a mix of regulatory approvals and pipeline filings accepted for review, Teva continues to build a comprehensive and diversified biosimilar portfolio that supports its evolution as a global biopharmaceutical leader.
In Europe, Teva had earlier secured marketing authorizations for PONLIMSI, following a positive opinion from the Committee for Medicinal Products for Human Use. These approvals underscore the company’s commitment to expanding access to important treatments across diverse geographies.
Looking ahead, the healthcare sector anticipates further advancements from Teva’s biosimilar pipeline, which includes additional candidates targeting key therapeutic categories. As regulatory milestones continue to be achieved, the company is poised to make a significant impact on global biologics accessibility while driving sustainable growth.
Overall, Teva’s recent regulatory successes reflect strong momentum within its biosimilar portfolio, signalling both scientific progress and strategic execution in the competitive landscape of biopharmaceutical innovation.
